Deoxycholic acid (ATX-101) is a secondary bile acid that was approved as an injectable drug for the reduction of submental fat. Necrosis, an uncommon but serious adverse event, can occur due to inadvertent superficial injection or intra-arterial injection of the acid. The management of the intra-arterial injection of deoxycholic acid has not been well characterized. Here, we discuss methods to decrease the risk of such injections and draw on existing protocols for the inadvertent intra-arterial injection of sclerotherapy solutions and dermal fillers to propose a safe, practical approach to treatment. A case report is presented of a 42-year-old woman who received a deoxycholic acid injection for the correction of submental fullness, which was complicated by the inadvertent intra-arterial injection of the acid. The adaptation of published treatment protocols for the inadvertent injection of sclerosing solutions and dermal fillers allowed for a good outcome in this patient. The inadvertent intra-arterial injection of deoxycholic acid is a rare event. The risk of such injections can be reduced with attention to injection technique and can be managed successfully following the adaptation of protocols in the literature for similar events from vascular compromise due to dermal fillers and sclerosing solutions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jocd.13214 | DOI Listing |
Cardiovasc Intervent Radiol
January 2025
Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences, Tehran, Iran.
This article provides radiologists with insights into stem cells' functions, sources, and potentially successful clinical treatments via intravascular injection in organs such as the liver, kidney, pancreas, musculoskeletal system, and for ischemic conditions affecting the brain, heart and limbs. Understanding stem cells' significance in interventional radiology and its limitations enables tailored interventions for diverse conditions, ensuring efficient medical care and optimal treatment selection.
View Article and Find Full Text PDFJ Extracell Vesicles
January 2025
Shanghai Jiao Tong University Affiliated Sixth People's Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Extracellular vesicles (EVs) have shown great potential for treating various diseases. Translating EVs-based therapy from bench to bedside remains challenging due to inefficient delivery of EVs to the injured area and lack of techniques to visualize the entire targeting process. Here we developed a dopamine surface functionalization platform that facilitates easy and simultaneous conjugation of targeting peptide and multi-mode imaging probes to the surface of EVs.
View Article and Find Full Text PDFNucl Med Commun
February 2025
Department of Radiology, Netherlands Cancer Institute- Antoni van Leeuwenhoekziekenhuis, Amsterdam, The Netherlands.
Background: Small-molecule biomacromolecules target tumor-specific antigens. They are employed as theranostic agents for imaging and treatment. Intravenous small-molecule radioligands exhibit rapid tumor uptake and excretion.
View Article and Find Full Text PDFBMC Cardiovasc Disord
December 2024
Departmentof Cardiology, Wuhan Asia Heart Hospital, Wuhan, China.
Background: Coronary Artery Spasm (CAS) often presents in the epicardial coronary arteries. The anterior septal branch is distributed within the myocardium, and occurrences of spasms are rare. Currently, there is no available literature on this topic, and the onset of symptoms remains elusive, potentially leading to misdiagnosis.
View Article and Find Full Text PDFJAAPA
January 2025
At the University of Toledo in Toledo, Ohio, Andrew Overholser is an assistant professor in the PA program and practices in the Department of Family Medicine, Megan Sizemore is an assistant professor and clinical pharmacist in the Department of Family Medicine, and Eric Czech is an assistant professor in the PA program and practices in the Department of Family Medicine. The authors have disclosed no potential conflicts of interest, financial or otherwise.
The Institute for Safe Medication Practices and the American Society of Health-System Pharmacists have advocated for removing all injectable promethazine from inpatient and outpatient settings; however, this drug is still being used despite the risk for tissue necrosis, gangrene, and possible amputation when it inadvertently is given by the subcutaneous or intra-arterial route. This article describes alternative injectable medications that can be selected based on patient comorbidities, indications, and clinician experience.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!